France announces first successful trials of COVID-19 vaccine

The covid-19 pandemic has so far taken about 16,000 lives worldwide. With over 360,000 now infected, scientists worldwide are racing to find a vaccine to stop the pandemic.

France announces first successful trials of COVID-19 vaccine
France announces first successful trials of COVID-19 vaccine

A group of French researchers have announced the successful results of the first clinical trials against coronavirus. Specialists at the Méditerranée Infection university hospital in Marseille suggest that the new coronavirus could be cured with a combination of two existing drugs: the antimalarial drug hydroxychloroquine and the broad-spectrum antibiotic azithromycin.

The vaccines were injected into 36 people, although it should be noted that not all had the symptoms of the pandemic.

Of the 36 people, 20 patients received 200 mg of hydroxychloroquine sulfate three times a day. Six of them also took 500 mg of azithromycin a day for the first two days and 250 mg the next four days.

The remaining 16 people formed the control group that was not supplied with the above-mentioned substances.

“Promising” results

According to the obtainedresults , “six members resisted the combination of the two drugs well, testing negative for coronavirus as early as day five, while those taking only hydroxychloroquine showed a 50% level of recovery on day five, compared to 18.8% in the control group”.

Interestingly, one patient who continued to test positive after being treated with hydroxychloroquine alone, was given azithromycin on the eighth day and tested negative the next day.

While the results appear to be positive, experts prefer to remain calm. The limited number of patients does not give a safe percentage at the macro level of what the application of these doses could achieve.

In their report published in the International Journal of Antimicrobial Agents, the researchers describe the results as “promising”, although they admit the need for further clinical trials.

Leave your comments